Valuation: Adocia

Market Cap 77.48M 89.13M 72.12M 66.21M 125M 8.51B 127M 850M 334M 4.24B 335M 327M 14.2B P/E 2026 *
-723x
P/E 2027 * 5.73x
Enterprise Value 47.64M 54.8M 44.34M 40.71M 76.88M 5.23B 78.07M 523M 205M 2.6B 206M 201M 8.73B EV / Sales 2026 *
18.9x
EV / Sales 2027 * 3.04x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.17%
1 week+6.97%
1 month-2.54%
3 months-15.36%
6 months-33.72%
Current year-37.85%
1 week 3.83
Extreme 3.832
3.99
1 month 3.68
Extreme 3.68
4.33
Current year 3.68
Extreme 3.68
7.35
1 year 3.68
Extreme 3.68
11.4
3 years 3
Extreme 2.995
15.72
5 years 2.74
Extreme 2.745
15.72
10 years 2.74
Extreme 2.745
62.12
Manager TitleAgeSince
Chief Executive Officer 55 10/05/2023
Director of Finance/CFO - 22/09/2024
Chief Tech/Sci/R&D Officer - 30/11/2014
Director TitleAgeSince
Director/Board Member 55 18/04/2013
Chairman 80 23/02/2012
Director/Board Member 58 17/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
+1.17%+6.97% - - 89.13M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average +0.00%-3.79%+35.87%+154.81% 25.98B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2026 *2027 *
Net sales 2.52M 2.9M 2.35M 2.15M 4.07M 277M 4.13M 27.66M 10.86M 138M 10.89M 10.65M 462M 35.4M 40.72M 32.95M 30.25M 57.13M 3.89B 58.01M 388M 152M 1.94B 153M 150M 6.49B
Net income -4.32M -4.97M -4.02M -3.69M -6.97M -474M -7.07M -47.37M -18.59M -236M -18.65M -18.24M -791M -44.33M -50.99M -41.26M -37.88M -71.54M -4.87B -72.64M -486M -191M -2.42B -192M -187M -8.13B
Net Debt -29.84M -34.33M -27.78M -25.5M -48.16M -3.28B -48.91M -327M -129M -1.63B -129M -126M -5.47B 30.18M 34.71M 28.09M 25.79M 48.7M 3.31B 49.45M 331M 130M 1.65B 130M 128M 5.53B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Date Price Change
31/07/26 €3.990 +1.17%
30/07/26 €3.944 +0.36%
29/07/26 €3.930 +1.76%
28/07/26 €3.862 +0.78%
27/07/26 €3.832 +2.73%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.960EUR
Average target price
9.700EUR
Spread / Average Target
+144.95%

Quarterly revenue - Rate of surprise